相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rethinking value in health innovation: from mystifications towards prescriptions
Mariana Mazzucato et al.
JOURNAL OF ECONOMIC POLICY REFORM (2019)
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
Pierre Azoulay et al.
REVIEW OF ECONOMIC STUDIES (2019)
Contribution of NIH funding to new drug approvals 2010-2016
Ekaterina Galkina Cleary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Fundamental science behind today's important medicines
Jonathan M. Spector et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
NIH Support for FDA-Approved Medicines
Rebekah H. Griesenauer et al.
CELL CHEMICAL BIOLOGY (2017)
Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom
Jon Sussex et al.
BMC MEDICINE (2016)
The High Cost of Prescription Drugs in the United States Origins and Prospects for Reform
Aaron S. Kesselheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
Use the Bayh-Dole Act to lower drug prices for government healthcare programs
Alfred B. Engelberg et al.
NATURE MEDICINE (2016)
Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy
Ranjana Chakravarthy et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2016)
The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs
Aaron S. Kesselheim et al.
HEALTH AFFAIRS (2015)
Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study
Carolyn L. Treasure et al.
MILBANK QUARTERLY (2015)
The $2.6 Billion Pill - Methodologic and Policy Considerations
Jerry Avorn
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Drug Development and FDA Approval, 1938–2013
Jonathan J. Darrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987-2011
Michael Lanthier et al.
HEALTH AFFAIRS (2013)
Patents, Profits, and the American People The Bayh-Dole Act of 1980
Howard Markel
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Accountability in patenting of federally funded research
Arti K. Rai et al.
NATURE BIOTECHNOLOGY (2012)
What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?
Bhaven N. Sampat et al.
HEALTH AFFAIRS (2011)
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines.
Ashley J. Stevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The importance of new companies for drug discovery: origins of a decade of new drugs
Robert Kneller
NATURE REVIEWS DRUG DISCOVERY (2010)
Perspectives on the development of imatinib and the future of cancer research
Brian J. Druker
NATURE MEDICINE (2009)
Drug prices and research and development investment behavior in the pharmaceutical industry
C Giaccotto et al.
JOURNAL OF LAW & ECONOMICS (2005)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Learning to patent: Institutional experience, learning, and the characteristics of US university patents after the Bayh-Dole Act, 1981-1992
DC Mowery et al.
MANAGEMENT SCIENCE (2002)
分享论文
